OUR TEAM. OUR MISSION.
The QbDVision project was started by two serial entrepreneurs and pharmaceutical manufacturing and quality experts. Our mission is to provide software solutions for the simple application of quality-by-design principles to the development of therapeutics and medical devices reducing development time and reducing the risk of encountering a systemic failure later in the development life cycle.
Board of Directors
Yash Sabharwal is an accomplished inventor, entrepreneur, and executive specializing in the funding and growth of early stage technology companies focused on life science applications.
After completing his Ph.D. in Optical Sciences at the University of Arizona, Yash co-founded Optical Insights, a company focused on the commercialization of imaging platforms and analytical software for fluorescence microscopy, medical imaging and drug discovery applications. He also served as CFO of the company where he successfully negotiated the sale of the company to Roper Industries in 2005.
In 2011, Yash co-founded his second startup, Xeris Pharmaceuticals and served as their COO/CFO. His primary responsibilities included oversight of drug development and manufacturing operations including implementation of Quality-By-Design methodologies, supply chain management, quality system implementation. As a key member of the founding management team, Yash helped Xeris raised over $75M in private and non-dilutive funding rounds including numerous SBIR awards from NIH.
As Chief Operating Officer at Xeris Pharmaceuticals, Yash realized he had a problem. He wanted to manage the development of the drug manufacturing process for their lead product using a quality-by-design framework. But, there weren't any integrated software tools available to specifically do this. Yash left Xeris in 2016 to start CherryCircle Software and the QbDVision project.
Emma Cartmell is a distinguished leader in the broader healthcare space. Having served in multiple C-level positions for both public and private companies, she brings deep expertise in the healthcare technology industry. She has developed M&A strategies for public and private companies on both the buy and sell-side, with investment targets of up to $1B. Under her leadership and guidance, healthcare companies have created and brought to market successful products and services that have led to meaningful impact and successful exits.
Emma serves on the boards of the following companies and industry associations: HIMSS North America (non-profit), Austin Healthcare Council (non-profit), Morgan Stanley’s Equity Expansion Fund and multiple leading healthcare companies, including Medsphere, B.Well, Care.Coach and Accordion Health (acquired in 2017). In 2013, Emma was appointed as an advisor to both the U.S. and British governments on healthcare technology trade and investment, and she presents regularly at Health DataPalooza, ATA and HIMSS on the international venture capital market for digital health.
In 2017, Emma was awarded the John. A Page Outstanding Service Award at HIMSS17 for her leadership in HIMSS and the Healthcare Industry. She is a native of the UK and a resident of Austin, Texas. Emma holds a Master of Science degree from King’s College London.
Pasquale (Pat) Sacco
Pat Sacco is a Biotechnology Technical Operations Executive with extensive experience in leading and managing technical operations functions, within the biotech and life sciences industries. He currently serves as SVP, Technical Operations at Translate Bio, Inc., an mRNA therapeutics company developing potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Throughout his 30+ year career, he has been recognized for guiding organizations through rapid change, growth, and transformation, while creating significant organizational capability, driving continuous process improvement, establishing lean operations, and increasing sustainable regulatory compliance.
Prior to joining Translate Bio, Pat served as SVP Manufacturing and Site Operations at Shire Pharmaceuticals. In this role, he led the internal manufacturing organization and site operations, managing 750+ staff, a $400M operating budget, multiple plants and warehouses, and producing three commercial and several biologic products in clinical development. He is passionate about the advancement and implementation of best practices in pharmaceutical manufacturing.